Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2017 Dec 22;71(5):391–397. doi: 10.1038/icb.1993.45

Recombinant fowlpox virus vaccines for poultry

D B BOYLE 1, H G HEINE 1
PMCID: PMC7165850  PMID: 8270268

Summary

The intensive poultry industries rely heavily upon the use of vaccines for disease control. Viral vector based vaccines offer new avenues for the development of vaccines for effective disease control in poultry. Techniques developed for the construction of recombinant vaccinia viruses have been readily adapted to the construction of recombinant viruses based on fowlpox virus (rFPV). The ability to insert several genes into the large genome of fowlpox may enable the development of multivalent vaccines and vaccines incorporating immune response modifiers such as lymphokines. Newcastle disease, avian influenza, infectious bursal disease and Marek's disease antigens expressed by rFPV have been shown to be effective vaccines in poultry. None appear, however, to provide a substantial improvement in vaccine efficacy. Recombinant FPV will be a valuable adjunct to conventional vaccines currently in widespread use. Whether rFPV or other vector based vaccines can circumvent the problems of vaccination in the presence of high maternally derived antibodies is yet to be resolved. The observation that avipoxvirus recombinants may be suitable for the vaccination of non‐avian species provides an added dimension to vaccines based on FPV or other avipoxviruses. Recombinant FPV will find a useful role in poultry disease control when used in conjunction with conventional vaccines.

Keywords: Key words: fowlpox virus, poultry, recombinant fowlpox virus, vaccines

References

  • 1. Panicali, D. and Paoletti, E. 1982. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA 79: 4927–4931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Mackett, M. , Smith, G. L. and Moss, B. 1982. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA 79: 7415–7419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Boyle, D. B. and Radford, A. J. 1992. Vectors for recombinant vaccine delivery In Animal Parasite Control Utilizing Biotechnology, Yong W. K. (ed.). CRC Press, Boca Raton, pp. 25–47. [Google Scholar]
  • 4. Esposito, J. J. and Murphy, F. A. 1989. Infectious recombinant vectored virus vaccines. Adv. Vet. Sci. Comp. Med. 33: 195–247. [DOI] [PubMed] [Google Scholar]
  • 5. Piccini, A and Paoletti, E. 1988. Vaccinia: Virus, vector, vaccine. Adv. Virus. Res. 34: 43–64. [DOI] [PubMed] [Google Scholar]
  • 6. Boyle, D. B. and Coupar, B. E. H. 1988. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res. 10: 343–356. [DOI] [PubMed] [Google Scholar]
  • 7. Boursnell, M. E. G. , Green, P. F. , Campbell, J. I. A. et al. 1990. Insertion of the fusion gene from Newcastle disease virus into a nonessential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant. J. Gen. Virol. 71: 621–628. [DOI] [PubMed] [Google Scholar]
  • 8. Spehner, D. , Drillien, R. and Lecocq, J‐P. 1990. Construction of fowlpox virus vectors with intergenic insertions: Expression of the β‐galactosidase gene and the measles virus fusion protein. J. Virol. 64: 527–533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Taylor, J. , Weinberg, R. , Languet, B. et al. 1988. Recombinant fowlpox virus inducing protective immunity in non‐avian species. Vaccine 6: 497–503. [DOI] [PubMed] [Google Scholar]
  • 10. Boyle, D. B. 1992. Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. Virus Genes 6: 281–290. [DOI] [PubMed] [Google Scholar]
  • 11. Boursnell, M. E. G. 1992. Avipoxvirus vectors In Recombinant Poxviruses, Binns M. M. and Smith G. L. (eds). CRC Press, Boca Raton, pp. 269–283. [Google Scholar]
  • 12. Stuart, J. C. 1989. Acute infectious bursal disease in poultry, [letter] Vet. Rec. 125: 281. [DOI] [PubMed] [Google Scholar]
  • 13. Bayliss, C. D. , Peters, R. W. , Cook, J. K. A. et al. 1991. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus. Arch. Virol. 120: 193–205. [DOI] [PubMed] [Google Scholar]
  • 14. Heine, H‐G. and Boyle, D. B. 1993. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch. Virol. (in press). [DOI] [PubMed] [Google Scholar]
  • 15. Tomley, F. M. , Mockett, A. P. A. , Boursnell, M. E. G. et al. 1987. Expression of the infectious bronchitis virus spike protein by recombinant vaccinia virus and induction of neutralizing antibodies in vaccinated mice. J. Gen. Virol. 68: 2291–2298. [DOI] [PubMed] [Google Scholar]
  • 16. Ogawa, R. , Yanagida, N. , Saeki, S. et al. 1990. Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses. Vaccine 8: 486–490. [DOI] [PubMed] [Google Scholar]
  • 17. Boursnell, M. E. G. , Green, P. F. , Samson, A. C. R. et al. 1990. A recombinant fowlpox virus expressing the hemagglutinin‐neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology 178: 297–300. [DOI] [PubMed] [Google Scholar]
  • 18. Taylor, J. , Edbauer, C. , Rey‐Senelongne, A. et al. 1990. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J. Virol. 64: 1441–1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Boursnell, M. E. G. , Green, P. F. , Samson, A. C. R. et al. 1990. A recombinant fowlpox virus expressing the hemagglutinin‐neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology 178: 297–300. [DOI] [PubMed] [Google Scholar]
  • 20. Edbauer, C. , Weinberg, R. , Taylor, J. et al. 1990. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin‐neuraminidase gene. Virology 179: 901–904. [DOI] [PubMed] [Google Scholar]
  • 21. Letellier, C. Burny, A. and Meulemans, G. 1991. Construction of a pigeonpox virus recombinant: Expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge Arch. Virol. 118: 43–56. [DOI] [PubMed] [Google Scholar]
  • 22. Iritani, Y. , Aoyama, S. Takigami, S. et al. 1991. Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinnin‐neuraminidase of NDV into chickens in the presence of antibody to NDV and FPV. Avian Dis. 35: 659–661. [PubMed] [Google Scholar]
  • 23. Taylor, J. , Weinberg, R. , Kawaoka, Y. et al. 1988. Protective immunity against avian influenza induced by a fowlpox virus recombinant Vaccine 6: 504–508. [DOI] [PubMed] [Google Scholar]
  • 24. Webster, R. G. , Kawaoka, Y. , Taylor, J. et al. 1991. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9: 303–308. [DOI] [PubMed] [Google Scholar]
  • 25. Tripathy, D. N. and Schnitzlein, W. M. 1991. Expression of avian influenza virus haemagglutinin by recombinant fowlpox virus. Avian Dis. 35: 186–191. [PubMed] [Google Scholar]
  • 26. Beard, C. W. , Schnitzlein, W. M. and Tripathy, D. N. 1991. Protection of chickens Fowlpox virus recombinants against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses. Avian Dis. 35: 356–359. [PubMed] [Google Scholar]
  • 27. Beard, C. W. , Schnitzlein, W. M. and Tripathy, D. N. 1992. Effect of route of administration on the efficacy of a recombinant fowlpox virus against H5N2 avian influenza. Avian Dis. 36: 1052–1055. [PubMed] [Google Scholar]
  • 28. Andrew, M. E. , Coupar, B. E. H. , Boyle, D. B. et al. 1987. The roles of influenza virus haemagglutinin and nucleoprotein in protection: Analysis using vaccinia virus recombinants. Scand. J. Immunol. 25: 221–228. [DOI] [PubMed] [Google Scholar]
  • 29. Andrew, M. E. A. and Coupar, B. E. H. 1988. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand. J. Immunol. 28: 81–85. [DOI] [PubMed] [Google Scholar]
  • 30. Stitz, L. , Schmitz, C , Binder, D. et al. 1990. Characterization and immunological properties of influenza A virus nucleoprotein (NP): Cell associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J. Gen. Virol. 71: 1169–1179. [DOI] [PubMed] [Google Scholar]
  • 31. Nazerian, K. , Lee, L. F. , Yanagida, N. et al. 1992. Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus. J. Virol. 66: 1409–1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Johnson, M. P. , Meitin, C. A. , Bender, B. S. et al. 1988. Passive immune serum inhibits antibody response to recombinant vaccinia virus In Vaccines 88: New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial and Parasitic Diseases. Ginsberg H., Brown F., Lerner R. A. et al. (eds). Cold Spring Harbor Laboratory, New York, pp. 189–192. [Google Scholar]
  • 33. Murphy, B. R. , Olmsted, R. A. , Collins, P. L et al. 1989. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol. 62: 3907–3910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Murphy, B. R. , Collins, P. L. , Lawrence, L. et al. 1898. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre‐existing serum antibodies: Partial prevention by topical infection of the respiratory tract with vaccinia virus‐RSV recombinants. J. Gen. Virol. 70: 2185–2190. [DOI] [PubMed] [Google Scholar]
  • 35. Xiang, Z. Q. and Ertl, H. C. J. 1992. Transfer of maternal antibodies results in inhibition of specific immune responses in the offspring. Virus Res. 24: 297–314. [DOI] [PubMed] [Google Scholar]
  • 36. Taylor, J. and Paoletti, E. 1988. Fowlpox virus as a vector for non‐avian species. Vaccine 6: 466–468. [DOI] [PubMed] [Google Scholar]
  • 37. Taylor, J. , Weinberg, R. , Languet, B. et al. 1988. Recombinant fowlpox virus inducing protective immunity in non‐avian species. Vaccine 6: 497–503. [DOI] [PubMed] [Google Scholar]
  • 38. Taylor, J. , Trimarchi, C. , Weinberg, R. et al. 1991. Efficacy studies on a canarypoxrabies recombinant virus. Vaccine 9: 190–193. [DOI] [PubMed] [Google Scholar]
  • 39. Cadoz, M. , Strady, A. , Meignier, B. et al. 1992. Immunisation of man with canarypox virus expressing rabies glycoprotein. Lancet 339: 1429–1432. [DOI] [PubMed] [Google Scholar]
  • 40. Wild, F. , Giraudon, P. , Spehner, D. et al. 1990. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine 8: 441–442. [DOI] [PubMed] [Google Scholar]

Articles from Immunology and Cell Biology are provided here courtesy of Wiley

RESOURCES